Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.
Company profile
Ticker
CNSTQ
Exchange
Website
CEO
Jigar Raythatha
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
131889304
Latest filings (excl ownership)
15-12G
Securities registration termination
30 Mar 11
NO ACT
No action letter
29 Mar 11
NO ACT
No action letter
29 Mar 11
NO ACT
No action letter
29 Mar 11
NO ACT
No action letter
29 Mar 11
8-K
Regulation FD Disclosure
25 Mar 11
8-K
Amendment No. 1 to Senior Secured Priming Super-priority Debtor In Possession Note Purchase Agreement
15 Mar 11
25-NSE
Exchange delisting
18 Feb 11
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Feb 11
8-K
Entry into a Material Definitive Agreement
18 Jan 11
Latest ownership filings
11-K
Annual report of employee stock purchases
25 Jun 09
11-K
Annual report of employee stock purchases
26 Jun 08
11-K
Annual report of employee stock purchases
28 Jun 07
11-K
Annual report of employee stock purchases
26 Jun 06
11-K
Annual report of employee stock purchases
28 Jun 05
11-K
Annual report of employee stock purchases
28 Jun 04
11-K
Annual report of employee stock purchases
30 Jun 03